IL239244A0 - Pyrimido[4,5-b] quinoline-5, 4 (3h,10h) - discussions as suppressors of non-sense mutations - Google Patents

Pyrimido[4,5-b] quinoline-5, 4 (3h,10h) - discussions as suppressors of non-sense mutations

Info

Publication number
IL239244A0
IL239244A0 IL239244A IL23924415A IL239244A0 IL 239244 A0 IL239244 A0 IL 239244A0 IL 239244 A IL239244 A IL 239244A IL 23924415 A IL23924415 A IL 23924415A IL 239244 A0 IL239244 A0 IL 239244A0
Authority
IL
Israel
Prior art keywords
pyrimido
diones
quinoline
nonsense mutation
mutation suppressors
Prior art date
Application number
IL239244A
Other languages
English (en)
Hebrew (he)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50030361&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL239244(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL239244A0 publication Critical patent/IL239244A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Inorganic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL239244A 2012-12-13 2015-06-04 Pyrimido[4,5-b] quinoline-5, 4 (3h,10h) - discussions as suppressors of non-sense mutations IL239244A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261736748P 2012-12-13 2012-12-13
PCT/IB2013/060859 WO2014091446A1 (en) 2012-12-13 2013-12-12 Pyrimido [4,5-b]quinoline-4,5 (3h,10h)-diones as nonsense mutation suppressors

Publications (1)

Publication Number Publication Date
IL239244A0 true IL239244A0 (en) 2015-07-30

Family

ID=50030361

Family Applications (1)

Application Number Title Priority Date Filing Date
IL239244A IL239244A0 (en) 2012-12-13 2015-06-04 Pyrimido[4,5-b] quinoline-5, 4 (3h,10h) - discussions as suppressors of non-sense mutations

Country Status (24)

Country Link
US (2) US9649314B2 (OSRAM)
EP (1) EP2931282B1 (OSRAM)
JP (1) JP6076498B2 (OSRAM)
KR (1) KR101760586B1 (OSRAM)
CN (2) CN104837490B (OSRAM)
AP (1) AP2015008441A0 (OSRAM)
AU (1) AU2013358591B2 (OSRAM)
BR (1) BR112015013535A2 (OSRAM)
CA (1) CA2890692A1 (OSRAM)
CL (1) CL2015001610A1 (OSRAM)
CR (1) CR20150314A (OSRAM)
CU (1) CU20150061A7 (OSRAM)
EA (1) EA028673B1 (OSRAM)
ES (1) ES2709034T3 (OSRAM)
HK (1) HK1209637A1 (OSRAM)
IL (1) IL239244A0 (OSRAM)
IN (1) IN2015DN03998A (OSRAM)
MA (1) MA38157A1 (OSRAM)
MX (1) MX363437B (OSRAM)
PE (1) PE20151062A1 (OSRAM)
PH (1) PH12015501216A1 (OSRAM)
SG (1) SG11201503684WA (OSRAM)
TN (1) TN2015000262A1 (OSRAM)
WO (1) WO2014091446A1 (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA028673B1 (ru) 2012-12-13 2017-12-29 Новартис Аг ПИРИМИДО[4,5-b]ХИНОЛИН-4,5(3H,10H)ДИОНЫ В КАЧЕСТВЕ СУПРЕССОРОВ НОНСЕНС МУТАЦИЙ
EP3152207B1 (en) * 2014-06-03 2019-05-08 Novartis AG Pyridopyrimidinedione derivatives as suppressors of non-sens mutations
CN106459041B (zh) 2014-06-03 2018-10-16 诺华股份有限公司 嘧啶并[4,5-b]喹啉-4,5(3H,10H)-二酮衍生物
MY178379A (en) * 2014-06-03 2020-10-09 Novartis Ag Naphthyridinedione derivatives as suppressors of non-sense mutations
US10960018B2 (en) * 2016-04-15 2021-03-30 The Uab Research Foundation Methods and compounds for stimulating read-through of premature termination codons
US20210040074A1 (en) * 2018-03-06 2021-02-11 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Positive allosteric modulators of dopamine 1 receptor and method of use thereof
WO2019225625A1 (ja) * 2018-05-23 2019-11-28 京都薬品工業株式会社 リードスルー誘導剤およびその医薬用途
EP4211171A2 (en) 2020-09-10 2023-07-19 Precirix N.V. Antibody fragment against fap
MX2023008296A (es) 2021-01-13 2023-09-29 Monte Rosa Therapeutics Inc Compuestos de isoindolinona.
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
AU2023264245A1 (en) 2022-05-02 2024-12-19 Precirix N.V. Pre-targeting
WO2024194607A1 (en) 2023-03-17 2024-09-26 Tay Therapeutics Limited Pyrimido[4,5-b][1,5]naphthyridine-4,5(3h,10h)-dione derivatives for the treatment of diseases associated with ptc mutations, such as e.g. cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2884170B2 (ja) 1989-08-24 1999-04-19 株式会社フジモト・ブラザーズ 5−デアザフラビン系化合物を有効成分とする制癌剤
WO1996028444A1 (en) * 1995-03-15 1996-09-19 Pfizer Inc. 5,10-DIHYDROPYRIMIDO[4,5-b]QUINOLIN-4(1H)-ONE TYROSINE KINASE INHIBITORS
US6468990B1 (en) 1999-05-17 2002-10-22 Queen's University At Kingston Method of inhibiting binding of nerve growth factor to p75 NTR receptor
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
AU2003249244A1 (en) 2002-07-15 2004-02-02 Combinatorx, Incorporated Methods for the treatment of neoplasms
PT2910551T (pt) 2003-04-11 2017-05-22 Ptc Therapeutics Inc Compostos do ácido 1,2,4-oxadiazole benzóico e a sua utilização para a supressão sem sentido e o tratamento de doenças
CA2646407C (en) 2006-04-03 2015-08-18 Technion Research & Development Foundation Ltd. Novel aminoglycosides and uses thereof in the treatment of genetic disorders
TW200819454A (en) 2006-08-23 2008-05-01 Neurogen Corp Haloalkyl-substituted pyrimidinone derivatives
WO2009086303A2 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP2422817A1 (en) 2010-07-29 2012-02-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Flavin-nucleic acid ligand conjugates
DK2600865T3 (en) 2010-08-05 2019-02-25 Univ Lille Compound for the treatment of nonsense mutation-mediated diseases as well as pharmaceutical composition comprising this compound
EA028673B1 (ru) 2012-12-13 2017-12-29 Новартис Аг ПИРИМИДО[4,5-b]ХИНОЛИН-4,5(3H,10H)ДИОНЫ В КАЧЕСТВЕ СУПРЕССОРОВ НОНСЕНС МУТАЦИЙ

Also Published As

Publication number Publication date
EP2931282A1 (en) 2015-10-21
JP2016503003A (ja) 2016-02-01
PE20151062A1 (es) 2015-08-05
CU20150061A7 (es) 2015-12-23
KR20150092306A (ko) 2015-08-12
MX363437B (es) 2019-03-22
MA38157A1 (fr) 2016-12-30
AU2013358591A1 (en) 2015-05-28
CN104837490A (zh) 2015-08-12
BR112015013535A2 (pt) 2017-07-11
JP6076498B2 (ja) 2017-02-08
TN2015000262A1 (en) 2016-10-03
CR20150314A (es) 2015-08-10
US20170266189A1 (en) 2017-09-21
EA201591105A1 (ru) 2015-10-30
CN104837490B (zh) 2017-10-03
AU2013358591B2 (en) 2016-08-25
CN107569487A (zh) 2018-01-12
CA2890692A1 (en) 2014-06-19
WO2014091446A1 (en) 2014-06-19
MX2015007562A (es) 2015-10-14
SG11201503684WA (en) 2015-06-29
PH12015501216A1 (en) 2015-08-17
AP2015008441A0 (en) 2015-05-31
US20150335646A1 (en) 2015-11-26
US9649314B2 (en) 2017-05-16
HK1209637A1 (en) 2016-04-08
IN2015DN03998A (OSRAM) 2015-10-02
CL2015001610A1 (es) 2015-08-07
KR101760586B1 (ko) 2017-07-21
EA028673B1 (ru) 2017-12-29
EP2931282B1 (en) 2018-10-31
ES2709034T3 (es) 2019-04-12

Similar Documents

Publication Publication Date Title
IL239244A0 (en) Pyrimido[4,5-b] quinoline-5, 4 (3h,10h) - discussions as suppressors of non-sense mutations
IL240402A (en) Tetrahydroimidazo derivative [d – 5,1] [4,1] oxazepine
ZA201408843B (en) Imidazo[1,2-b]pyridazine derivative as kinase inhibitor
IL254224A0 (en) 7-substituted 5-alkyl-[4,2,1]triazolo[5,1-a]pyrimidine derivatives as pde2 inhibitors
IL234485A (en) Compounds based on imidazo [2,1 – b] pyridazine
EP2968311A4 (en) OXAZOLO [5,4-C] CHINOLIN-2-ON COMPOUNDS AS BROMODOMENA INHIBITORS
IL243092B (en) New triazolo[d–4,5]pyrimidine histories
AP2014007820A0 (en) PDE9 inhibitors with imidazo triazinone backbone
HUE045663T2 (hu) Pteridinek, mint FGFR inhibitorok
ZA201407828B (en) Bicyclic pyrazinone derivatives
HUE043108T2 (hu) (5,6-dihidro)pirimido[4,5-e]indolizinek
ZA201406323B (en) Triazolo[4,5-d]pyrimidine derivatives
EP2801439A4 (en) VERTICAL MACHINING CENTER
PL2694513T3 (pl) Pochodne pirazolopirymidynowe
GB201313823D0 (en) Axisymmetrical Intermediate Case Part Including an Insert positioned in an Annular Groove
ZA201507151B (en) Antiviral indolo[2,3-b]quinoxaline
IL236808B (en) Piperazino[1,2-a]indol-1-ones and [1,4]diazepino[1,2-a]indol-1-one
GB2501283B (en) Microbiological safety cabinets
GB201211756D0 (en) Novel isothiazolo [4,3-b]pyridines
GB201219129D0 (en) Triazolo(4,5-d)pyrmindine compounds
AU344103S (en) Modular outdoor seating
GB201221462D0 (en) Novel isothiazolo[5,4-b]pyridines
GB201213663D0 (en) Novel isothiazolo[5,4-b]pyridines
PH22012000559U1 (en) Multi-purpose stool